Private Equity
Menlo Park, California-based Menlo Therapeutics Inc, a pharmaceutical company focused on treating chronic pruritus and chronic cough, has raised $119 million for its IPO after pricing its 7 million shares at $17 per share. The stock began trading January 25, 2018 on the NASDAQ under the ticker symbol "MNLO." Jefferies LLC, Piper Jaffray & Co. and Guggenheim Securities LLC are the lead underwriters. The investors included VenBio, Novo Holdings A/S, Rock Springs Capital, Aisling Capital, Bay City Capital, Vivo Capital, Presidio Partners, Remeditex and F-Prime Capital.
3 min read · 25 January 2018
1 min read · 25 January 2018
2 min read · 25 January 2018
Champaign, Illinois-based Inprentus, a maker of X-ray and EUV diffraction gratings for synchrotron radiation facilities, has secured a total of $2.5 million in Series A funding. Flyover Capital led the round with participation from other investors that included Serra Ventures.
1 min read · 24 January 2018
MFV Partners has set out to raise a $75 million maiden venture-capital fund, according to a filing with the SEC.
1 min read · 24 January 2018
3 min read · 24 January 2018
Newport Beach, California-based Bonti, a biotechnology company, has secured $15.5 million in Series C financing. City Hill Ventures led the round. In addition to the funding, Bonti has named David Ramsay as chief financial officer. Ramsay is the former CFO of Halozyme Therapeutics Inc.
1 min read · 24 January 2018
San Jose, California-based Neuspera Medical Inc, a neuromodulation company, has secured $26 million in Series B financing. The lead investor was 6 Dimensions Capital. In addition to the funding, Dr. Ching Zhu, a managing partner at 6 Dimensions Capital, joined the Neuspera's board of directors.
1 min read · 24 January 2018
5 min read · 24 January 2018
1 min read · 24 January 2018
